1. Home
  2. NXL vs PTLE Comparison

NXL vs PTLE Comparison

Compare NXL & PTLE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NXL
  • PTLE
  • Stock Information
  • Founded
  • NXL 2010
  • PTLE 2013
  • Country
  • NXL United States
  • PTLE Singapore
  • Employees
  • NXL N/A
  • PTLE N/A
  • Industry
  • NXL Medical Specialities
  • PTLE Oil Refining/Marketing
  • Sector
  • NXL Health Care
  • PTLE Energy
  • Exchange
  • NXL Nasdaq
  • PTLE Nasdaq
  • Market Cap
  • NXL 14.0M
  • PTLE 16.4M
  • IPO Year
  • NXL 2022
  • PTLE 2024
  • Fundamental
  • Price
  • NXL $0.84
  • PTLE $0.16
  • Analyst Decision
  • NXL Strong Buy
  • PTLE
  • Analyst Count
  • NXL 1
  • PTLE 0
  • Target Price
  • NXL $5.00
  • PTLE N/A
  • AVG Volume (30 Days)
  • NXL 2.9M
  • PTLE 920.5K
  • Earning Date
  • NXL 08-06-2025
  • PTLE 01-01-0001
  • Dividend Yield
  • NXL N/A
  • PTLE N/A
  • EPS Growth
  • NXL N/A
  • PTLE N/A
  • EPS
  • NXL N/A
  • PTLE N/A
  • Revenue
  • NXL $174,813.00
  • PTLE $98,133,646.00
  • Revenue This Year
  • NXL $38.28
  • PTLE N/A
  • Revenue Next Year
  • NXL $185.71
  • PTLE N/A
  • P/E Ratio
  • NXL N/A
  • PTLE N/A
  • Revenue Growth
  • NXL 16.42
  • PTLE N/A
  • 52 Week Low
  • NXL $0.59
  • PTLE $0.15
  • 52 Week High
  • NXL $4.49
  • PTLE $15.78
  • Technical
  • Relative Strength Index (RSI)
  • NXL 45.15
  • PTLE 29.39
  • Support Level
  • NXL $0.78
  • PTLE $0.16
  • Resistance Level
  • NXL $0.99
  • PTLE $0.21
  • Average True Range (ATR)
  • NXL 0.12
  • PTLE 0.01
  • MACD
  • NXL 0.01
  • PTLE 0.00
  • Stochastic Oscillator
  • NXL 25.40
  • PTLE 9.44

About NXL Nexalin Technology Inc.

Nexalin Technology Inc designs and develops neurostimulation products to uniquely and effectively help combat the ongoing mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.

About PTLE PTL LTD Ordinary Shares

PTL Ltd is a holding company. Through its subsidiaries, it is an established bunkering facilitator providing marine fuel logistics services for vessel refuelling, primarily serving the Asia Pacific market. As a bunker facilitator, the Group's services mainly involve facilitating with its suppliers to supply fuel for the use by the customers' vessels at various ports along their voyages in the Asia Pacific region; arranging vessel refuelling activities at competitive pricing to the customers; offering trade credit to the customers for vessel refuelling; handling unforeseeable circumstances faced by the customers and providing contingency solutions to the customers in a timely manner; and handling disputes, mainly in relation to quality and quantity issues on marine fuel, if any.

Share on Social Networks: